Allianz SE Sells 23,225 Shares of Abbott Laboratories $ABT

Allianz SE cut its holdings in shares of Abbott Laboratories (NYSE:ABT) by 21.2% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 86,499 shares of the healthcare product maker’s stock after selling 23,225 shares during the period. Allianz SE’s holdings in Abbott Laboratories were worth $11,586,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of the business. Brighton Jones LLC lifted its stake in shares of Abbott Laboratories by 10.1% in the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after purchasing an additional 4,755 shares during the period. Sivia Capital Partners LLC increased its holdings in Abbott Laboratories by 3.5% in the second quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock valued at $648,000 after purchasing an additional 162 shares during the last quarter. United Bank lifted its stake in Abbott Laboratories by 7.4% in the second quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock valued at $3,945,000 after buying an additional 2,001 shares during the period. Premier Path Wealth Partners LLC boosted its holdings in Abbott Laboratories by 11.6% during the second quarter. Premier Path Wealth Partners LLC now owns 8,576 shares of the healthcare product maker’s stock worth $1,166,000 after buying an additional 892 shares during the last quarter. Finally, Assetmark Inc. grew its position in shares of Abbott Laboratories by 14.5% during the 2nd quarter. Assetmark Inc. now owns 181,491 shares of the healthcare product maker’s stock worth $24,685,000 after buying an additional 23,050 shares during the period. Institutional investors and hedge funds own 75.18% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on ABT. William Blair raised shares of Abbott Laboratories to a “strong-buy” rating in a research note on Thursday, November 20th. Sanford C. Bernstein lowered their price objective on shares of Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Barclays reduced their target price on Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating on the stock in a report on Monday, February 2nd. BTIG Research lowered their price target on Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating for the company in a report on Tuesday, February 17th. Finally, Oppenheimer cut their price objective on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, Abbott Laboratories presently has an average rating of “Moderate Buy” and an average price target of $137.05.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, Director Daniel J. Starks bought 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 4th. The shares were acquired at an average cost of $108.73 per share, with a total value of $1,087,300.00. Following the acquisition, the director owned 6,738,817 shares of the company’s stock, valued at $732,711,572.41. The trade was a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Stock Performance

NYSE ABT opened at $116.17 on Friday. The firm has a market capitalization of $201.87 billion, a P/E ratio of 31.23, a price-to-earnings-growth ratio of 1.85 and a beta of 0.75. The company has a current ratio of 1.58, a quick ratio of 1.24 and a debt-to-equity ratio of 0.19. The firm’s fifty day moving average price is $117.34 and its two-hundred day moving average price is $125.30. Abbott Laboratories has a 1 year low of $105.27 and a 1 year high of $141.23.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, hitting the consensus estimate of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The company had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. During the same period in the previous year, the business earned $1.34 EPS. Abbott Laboratories’s revenue for the quarter was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, research analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 67.74%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.